ACLX Stock Overview
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Arcellx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$75.54 |
| 52 Week High | US$107.37 |
| 52 Week Low | US$47.88 |
| Beta | 0.25 |
| 1 Month Change | -16.48% |
| 3 Month Change | -12.14% |
| 1 Year Change | 40.28% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 349.64% |
Recent News & Updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Arcellx, Inc. (NASDAQ:ACLX)
Dec 20
A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)
Oct 28Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
Sep 10There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump
Sep 05We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow
Aug 10A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)
Jul 12News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts
Jun 01Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic
May 14Is Arcellx (NASDAQ:ACLX) A Risky Investment?
May 12Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 01Arcellx: Navigating The CAR T-Cell Revolution
Jan 30Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues
Nov 18Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 10Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth
Nov 17Arcellx: The Best Is Yet To Come
Aug 23Arcellx GAAP EPS of -$0.88
Aug 15Arcellx down 9% on day lock-up period ends
Aug 03We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely
Jun 27Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy
Jun 08Shareholder Returns
| ACLX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.9% | -3.6% | -2.4% |
| 1Y | 40.3% | -2.6% | 23.4% |
Return vs Industry: ACLX exceeded the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: ACLX exceeded the US Market which returned 23.4% over the past year.
Price Volatility
| ACLX volatility | |
|---|---|
| ACLX Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACLX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACLX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 130 | Rami Elghandour | www.arcellx.com |
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Arcellx, Inc. Fundamentals Summary
| ACLX fundamental statistics | |
|---|---|
| Market cap | US$4.08b |
| Earnings (TTM) | -US$40.42m |
| Revenue (TTM) | US$155.82m |
26.2x
P/S Ratio-101.1x
P/E RatioIs ACLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACLX income statement (TTM) | |
|---|---|
| Revenue | US$155.82m |
| Cost of Revenue | US$7.38m |
| Gross Profit | US$148.44m |
| Other Expenses | US$188.86m |
| Earnings | -US$40.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 95.26% |
| Net Profit Margin | -25.94% |
| Debt/Equity Ratio | 0% |
How did ACLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:58 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arcellx, Inc. is covered by 22 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Peter Lawson | Barclays |
| Carter Gould | Barclays |